Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. - Wikidata - wikimedia - TriplyDB

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

http://www.wikidata.org/entity/Q33216729

about

MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs Improved endpoints for cancer immunotherapy trials Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.Is cancer vaccination feasible at older age?Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.The immuno-oncology framework: Enabling a new era of cancer therapy.Novel anti-melanoma treatment: focus on immunotherapy.Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer Pilot study of p62 DNA vaccine in dogs with mammary tumors A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87 Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).Biology of human cutaneous melanoma Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer.Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.MAGE A3 antigen-specific cancer immunotherapeutic.The biology of cancer testis antigens: putative function, regulation and therapeutic potential Melanoma vaccines: developments over the past 10 years.Targeting HLA class I expression to increase tumor immunogenicity.Role of immunotherapy in castration-resistant prostate cancer (CRPC).Aging and cancer vaccines.Update on vaccines for high-risk melanoma.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.Metastatic melanoma and immunotherapy

P2860

Q24298306-2CE25E79-3F82-4791-BE5A-206F9361FACB Q24603112-FE034223-6244-4E3A-A7CD-018F181E8800 Q28074295-3AAEE310-60C6-4C6E-B7C2-32D50EE3D4C8 Q30358552-15688745-DB89-4485-A8FC-C05DA8306D74 Q33421740-7C91A918-881F-4D0F-86A4-EB4C22A9C980 Q33739907-7E9A7716-191B-49D5-9BE1-45DBC299263D Q33862861-8F8CC18A-24E8-40BE-BEF1-4E4A358C7E50 Q34093600-06575476-5912-4D85-8A25-941D611C1117 Q34284462-8637569F-D8BE-41F1-AF7D-65FD8679D6A4 Q34309404-F049DEAE-E6D7-4F97-A39A-6155326BF717 Q34448082-3A187254-D8BD-463E-9B11-D4A7FC5ACCC4 Q34499626-4B59C17F-5F57-4680-8606-230C9874CCAB Q34687752-AB7AB28F-E037-455B-B75C-8E6EFBD1D38E Q35149622-21A94985-061A-46FD-9CA1-F8ED40918E7C Q35238022-1619E53A-6EEF-4E72-937B-3874B3AB39AA Q35774908-D10195AC-7FD9-4AD1-9746-E5135C65A5C5 Q35914325-05087A00-38B9-49B4-A62A-01A0FB99880B Q36419244-CDF8BF1B-F6A5-4E30-9692-8D76C5647A16 Q36446446-67FB243E-D94F-4653-A1D7-3A1090F5401D Q36637039-A3E60EEF-DDBA-4B97-9AF2-76EC57720734 Q36859171-23C3A769-BF91-412D-A300-2793ECA7097B Q36973053-61B77987-FD7D-436F-B02A-FF85616AB75B Q36983356-36C6DF9F-F076-43B7-B43A-E71C4DC244B3 Q37137360-13508181-EA09-4DB3-B94B-ED66FDC9D624 Q37281267-417B035E-B746-4918-A686-C8BBBC7CC084 Q37307195-C38A8C44-7C07-4A38-90C4-E12C175E2F1A Q37316009-7952F1C3-1D50-4963-82C4-4DE7DD616CDD Q37373941-2494E306-9EC7-4855-B2BB-1F1EBF9D7696 Q37560757-ED5AED29-6FB6-4124-9E16-53286F2E2EC0 Q37737327-50647790-964F-4129-8778-A100CD71BF34 Q37773275-189FE402-C60D-4243-B92F-0C6867FAFAE6 Q37849976-03280F1B-29E1-4AD4-AA96-6648516977AB Q37892595-E7DA6566-061E-4FC4-99E8-11941E64BD50 Q37981721-88A4BC24-5F86-41BE-BF98-8B1E19A64A2B Q38104730-5E17CFFB-B122-4572-AC33-FBFA75916815 Q38192000-CD1C4DD5-9EB4-42C4-9200-D31A1ADEDC71 Q38208715-4AB73FE8-229C-4F3A-A58F-B84F4955E63E Q38289581-8EBE59D9-B7B2-4A15-B270-A9E4E757D480 Q38447421-432CC956-FB14-49FF-B28E-AED036C6B12D Q38901338-8C729B7E-E880-43CE-97F5-ACEB2F6A5838

P2860

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

http://www.wikidata.org/entity/Q33216729

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@ast

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@en

type

label

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@ast

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@en

prefLabel

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@ast

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@en

P1433

Q33216729-3ACAA10C-BEFC-4959-8DF3-996B56B9AFD6

P1476

Q33216729-37CB481C-0FBC-42E6-85DD-AA8A1575E149

P2093

Q33216729-00C6393B-57AA-45AF-9463-64CB61EFAE13

Q33216729-0669B8F4-8069-440D-8E5F-68623AF52191

Q33216729-4F9411F1-A8BF-4C5B-AB2F-EECEA7CE56B0

Q33216729-55838226-F7A0-4653-BD45-8F8B5ADF9422

Q33216729-5745422B-1E43-446F-B85F-BEC2E54CE549

Q33216729-57FC8E06-A5C0-4278-962F-2C808465D8F4

Q33216729-7D1AB4B3-D5C3-4E14-8CCC-558DFD3CDB22

Q33216729-87D3B6D5-4DE3-4A27-9C46-1E9ADCB054EE

Q33216729-8BD3DBE4-3D69-4649-8B98-D0BE03F370BB

Q33216729-8F46CC6B-C155-428E-A514-9016732F7A01

P2860

Q33216729-15C7E241-E196-47CB-B6FD-10BD51AFA2BB

Q33216729-D697D956-2857-40AE-80A1-482F67AB2CC8

P304

Q33216729-43D81EF3-F73A-45E5-B2DF-D791B201E56A

P31

Q33216729-7491F992-B89A-4165-9159-AC604B2D57A1

P356

Q33216729-2582E791-F6F4-4D30-ACF5-7FB3A0F93975

P433

Q33216729-9EA49701-6985-4977-A9D0-B593CE4E0099

P478

Q33216729-C236EA50-3469-4AF4-8967-08545C56E056

P50

Q33216729-7D0E4A1A-27E0-479C-BED9-C4D3F53C305E

Q33216729-ECCC17ED-6DB8-48BD-9CE0-17AC37A49460

Q33216729-F62880A5-4B55-4F06-8F75-7A8A3E937D9F

P577

Q33216729-2BF7C322-322E-49DC-B814-377B5DCD82DE

P5875

Q33216729-45E29998-9295-479E-B085-4D92784B1314

P698

Q33216729-1F9EC167-6455-43FB-B1E7-0FF366B6C93D

P921

Q33216729-D15BE32B-F69D-4A4F-AB9B-5E9A2EDF7E7C

P356

P1433

International Journal of Cancer

P1476

Phase 1/2 study of subcutaneou ...... etectable metastatic melanoma.

@en

P2093

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Amir Khammari

http://www.w3.org/2001/XMLSchema#string

Bernard Lethé

http://www.w3.org/2001/XMLSchema#string

Danièle Godelaine

http://www.w3.org/2001/XMLSchema#string

Francis Brasseur

http://www.w3.org/2001/XMLSchema#string

Gerd Ritter

http://www.w3.org/2001/XMLSchema#string

Heidi H van Ojik

http://www.w3.org/2001/XMLSchema#string

Marguerite Stas

http://www.w3.org/2001/XMLSchema#string

Marie Marchand

http://www.w3.org/2001/XMLSchema#string

Marie-Françoise Avril

http://www.w3.org/2001/XMLSchema#string

P2860

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

P304

596-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.21264

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

Brigitte Dréno

Bernard Escudier

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7797502

http://www.w3.org/2001/XMLSchema#string

P698

15945101

http://www.w3.org/2001/XMLSchema#string

P921